




已阅读5页,还剩22页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Guidelines For Cardiovascular Prevention,Dr Chan, Ngai Yin, MBBS(HK), MRCP(UK), FRCP(Edin), FACC, FAHA, Associate Consultant, Director, Cardiac Pacing Services, Princess Margaret Hospital,10th South China International Congress in Cardiology, Guangzhou, China, April 12, 2008,CVD and other major causes of death: both sexes. (United States: 2004). Source: NCHS and NHLBI.,Causes of Death-US,57% of deaths due to CV diseases,Setting the Goal: A History,In 1998, the AHA Board of Directors adopted a 2010 Impact Goal: By 2010, to reduce coronary heart disease, stroke and risk by 25%. Risk factors to be measured included: Tobacco Usage High Blood Pressure High Cholesterol Physical Inactivity In 2001, Obesity and Diabetes were added as risk factors. Our goal is to achieve a 0% growth rate in Obesity and Diabetes by 2010.,Coronary Heart Disease Mortality,22.8%,Stroke Mortality,18.8%,AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update,Lifestyle modification Blood pressure control Lipid management Diabetes management Antithrombotic treatment Renin-Angiotensin-Aldosterone system blockade blockers Influenza vaccination,Lifestyle modification,Smoking -complete cessation, avoid environmental exposure Physical activity -30 minutes, 7 days per week (minimum 5 days per week) Weight management -BMI 18.5-24.9kg/m2, waist circumference 40 inches for men, 35 inches for women,One-for-all Community-Based Phase 2.5 Cardiac Rehabilitation for Low-risk Patients,Patients with implantable devices Class I and II heart failure patients Patients with coronary artery disease after complete revascularization Patients with stable angina with satisfactory medical control Patients with valvular heart disease after surgical treatment,Blood Pressure Control,Goal: 140/90mmHg or 130/80mmHg if patient has diabetes or chronic kidney disease Lifestyle modification As tolerated, add BP medication, treating initially with blockers and/or ACEI, with addition of other drugs such as thiazides,New Lipid Target (1),LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin In patients with stable coronary disease. NEJM 2005;352:1425-35,10001 pts with CHD And LDL130mg/dl Median FU 4.9years,Mean LDL 77 vs 101,LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin In patients with stable coronary disease. NEJM 2005;352:1425-35,Primary endpoint: First major CV event, defined as Death from CHD, Nonfatal MI Cardiac arrest survivor Fatal or nonfatal stroke Liver derangement: 1.2% vs 0.2% (p0.001),New Lipid Target (3),Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose Simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437-45,4439 (high dose) vs 4449 pts With history of MI Primary endpoint: Major coronary event defined as Coronary death, nonfatal AMI, or Cardiac arrest survivor No difference in CV or All-cause mortality,80mg Atorvastatin 20mg Simvastatin,New Lipid Target (4),Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose Simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437-45,New Lipid Target (4),Shephard J, Kastelein JJP, Bittner V et al. Intensive lipid lowering with atrovastatin in patients With coronary heart disease and chronic kidney disease. JACC 2008;51:1448-54,10001 pts with CHD 9656 with renal data 3107 CKD (GFR60ml/min/1.73m2 vs 6549 normal GFR,Lipid Management,Diet therapy LDL-C 100mg/dL, further reduction of LDL-C to 70mg/dL is reasonable If TG 200-499mg/dL, non-HDL-C should be 130mg/dL If TG 500mg/dL, prevent pancreatitis with fibrate or niacin before LDL lowering Lipid-lowering medications: statin, fibrate, niacin, bile acid sequestrants, ezetimibe,Diabetes Management,Lifestyle modification and pharmacotherapy Goal: HbA1c7%,Antithrombotic Therapy,Lifelong aspirin 75-162mg/d Aspirin 100-325mg/d within 48h of SVG, higher dose for 1 year Aspirin 325mg/d postPCI (1 month BMS, 3 months SES, 6 months PES) +Clopidogrel 75mg/d up to 12 months for ACS, postPCI (1 month BMS, 3 months SES, 6 months PES) Warfarin with INR 2-3 for PAF, CAF or flutter,Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease,Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting enzyme Inhibition in stable coronary artery disease. NEJM 2004;351:2058-69,P=0.43,8290 pts randomized 4mg trandolapril or placebo Primary endpoint: Death from CV causes, MI, Or coronary revascularization,Renin-Angiotensin-Aldosterone System Blockade,ACEI -LVEF40%, HT, DM, or CKD -Low-risk, normal LVEF, optional ARB -ACEI intolerant -Combination with ACEI in systolic heart failure Aldosterone blockade -post-MI patients, on ACEI and blocker, either DM or heart failure, LVEF40%, -Blockers,MI, ACS, or LVD with or without heart failure symptoms (I, A) All other patients with coronary or other vascular disease or dia
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025-2030中国海鲜行业市场发展分析及发展趋势与投资战略研究报告
- 2025-2030中国浴袍行业市场深度调研及竞争格局与投资研究报告
- 全国闽教版初中信息技术八年级下册第一单元第4课《搭建救援机器人》教学设计
- 2025-2030中国洗发水设备行业市场现状分析及竞争格局与投资发展研究报告
- 狸米面试题及答案
- 医学基础知识信息处理能力试题及答案
- 9《小水滴的诉说》(教学设计)-2023-2024学年统编版道德与法治二年级下册
- 2024年心理咨询师考试关键心理学概念的试题及答案
- 是否选择自报税务的利弊分析试题及答案
- 教师资格笔试重要试题及答案总结
- 2025届重庆市双福育才中学中考化学最后冲刺卷含解析
- 光伏项目承包商的实施策略与计划
- 管理学组织设计案例分析
- 消除艾滋病、梅毒和乙肝母婴传播项目工作制度及流程(模板)
- 2025年河南机电职业学院单招职业倾向性测试题库有完整答案
- 2025年度汽车行业电子商务平台合作开发合同
- 摄影拍摄合同毕业季拍摄合同
- 《个人所得税申报赡养老人专项附加扣除指定分摊协议模板》
- 国家一级博物馆运行报告2024
- 血液病早期发现-你不可忽视的健康防线
- 化工行业不合格品处理流程
评论
0/150
提交评论